Niagen Bioscience, Inc. Common Stock NAGE Income Statement
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| $129.42M+29.9% | $99.6M+19.2% | $83.57M— | ||
| $46.23M+21.6% | $38.01M+15.9% | $32.79M— | ||
| $83.19M+35.1% | $61.59M+21.3% | $50.78M— | ||
| 64.3%+2.4pp | 61.8%+1.1pp | 60.8%— | ||
| $6.33M+5.2% | $6.02M+21.3% | $4.96M— | ||
| $35.51M+20.5% | $29.47M+11.5% | $26.44M— | ||
| $27.06M+47.2% | $18.38M-26.4% | $24.98M— | ||
| $66.91M+24.2% | $53.86M-4.5% | $56.38M— | ||
| $16.28M+111% | $7.73M+238% | -$5.6M— | ||
| 12.6%+4.8pp | 7.8%+14.5pp | -6.7%— | ||
| $1.91M+69.4% | $1.13M+70.8% | $661K— | ||
| $2.13M+88.4% | $1.13M— | —— | ||
| —— | —— | —— | ||
| $18.19M+105% | $8.86M+279% | -$4.94M— | ||
| $810K+166% | $305K— | $0— | ||
| $17.38M+103% | $8.55M+269% | -$5.05M— | ||
| 13.4%+4.8pp | 8.6%+14.6pp | -6%— | ||
| $0.20+100% | $0.10+243% | -$0.07— | ||
| $0.23+130% | $0.10+243% | -$0.07— | ||
| 341.5M+11.4% | 306.7M+2.3% | 299.8M— | ||
| 316M+4.4% | 302.7M+1.0% | 299.8M— | ||
| $1.98M— | $0— | —— | ||
| $1.91M+69.4% | $1.13M+70.8% | $661K— | ||
| -$214K— | $0— | —— | ||
| —— | —— | —— | ||
| $16.28M+111% | $7.73M+238% | -$5.6M— | ||
| $17.06M+99.8% | $8.54M+287% | -$4.57M— | ||
| $17.06M+99.8% | $8.54M+287% | -$4.57M— | ||
| 13.2%+4.6pp | 8.6%+14.0pp | -5.5%— | ||
| $16.28M+111% | $7.73M+238% | -$5.6M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Niagen Bioscience, Inc. Common Stock's revenue?
- Niagen Bioscience, Inc. Common Stock (NAGE) generated $130.4M in revenue over the trailing twelve months, up 20.8% year over year.
- Is Niagen Bioscience, Inc. Common Stock profitable?
- Niagen Bioscience, Inc. Common Stock reported $18.6M in net income over the trailing twelve months, a 14.3% net margin.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Gross margin is 64.3% and operating margin is 10.0%, with a 14.3% net margin.
- What is Niagen Bioscience, Inc. Common Stock's earnings per share?
- Niagen Bioscience, Inc. Common Stock's diluted EPS over the trailing twelve months is $0.21.
- Where does Niagen Bioscience, Inc. Common Stock's income statement data come from?
- Every line is extracted from Niagen Bioscience, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
